Back to Search Start Over

TRPV1 nociceptors are required to optimize antigen-specific primary antibody responses to novel antigens.

Authors :
Tynan, Aisling
Tsaava, Téa
Gunasekaran, Manojkumar
Bravo Iñiguez, Carlos E.
Brines, Michael
Chavan, Sangeeta S.
Tracey, Kevin J.
Source :
Bioelectronic Medicine; 5/29/2024, Vol. 10 Issue 1, p1-9, 9p
Publication Year :
2024

Abstract

Background: Key to the advancement of the field of bioelectronic medicine is the identification of novel pathways of neural regulation of immune function. Sensory neurons (termed nociceptors) recognize harmful stimuli and initiate a protective response by eliciting pain and defensive behavior. Nociceptors also interact with immune cells to regulate host defense and inflammatory responses. However, it is still unclear whether nociceptors participate in regulating primary IgG antibody responses to novel antigens. Methods: To understand the role of transient receptor potential vanilloid 1 (TRPV1)-expressing neurons in IgG responses, we generated TRPV1-Cre/Rosa-ChannelRhodopsin2 mice for precise optogenetic activation of TRPV1 + neurons and TRPV1-Cre/Lox-diphtheria toxin A mice for targeted ablation of TRPV1-expressing neurons. Antigen-specific antibody responses were longitudinally monitored for 28 days. Results: Here we show that TRPV1 expressing neurons are required to develop an antigen-specific immune response. We demonstrate that selective optogenetic stimulation of TRPV1<superscript>+</superscript> nociceptors during immunization significantly enhances primary IgG antibody responses to novel antigens. Further, mice rendered deficient in TRPV1- expressing nociceptors fail to develop primary IgG antibody responses to keyhole limpet hemocyanin or haptenated antigen. Conclusion: This functional and genetic evidence indicates a critical role for nociceptor TRPV1 in antigen-specific primary antibody responses to novel antigens. These results also support consideration of potential therapeutic manipulation of nociceptor pathways using bioelectronic devices to enhance immune responses to foreign antigens. Summary: Genetic and selective functional evidence reveals that TRPV1<superscript>+</superscript> nociceptors are required for primary IgG antibody responses to novel antigens and stimulating TRPV1<superscript>+</superscript> nociceptors enhances primary IgG antibody responses to novel antigens. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
23328886
Volume :
10
Issue :
1
Database :
Complementary Index
Journal :
Bioelectronic Medicine
Publication Type :
Academic Journal
Accession number :
177539211
Full Text :
https://doi.org/10.1186/s42234-024-00145-6